MapLight Therapeutics MPLT
NASDAQ MPLT
$14.01 +0.87 (+6.62%)
As of: Sep 4, 2026 · 3:16 PM EDT

MapLight Therapeutics (MPLT) Research & Development (2024 - 2026)

MapLight Therapeutics (MPLT) posted Research & Development of $64.6 million for Q4 2025, up 138.51% sequentially from $27.1 million in Q3 2025, and up 211.99% YoY from $20.7 million in Q4 2024.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

MapLight Therapeutics (MPLT) Research & Development (2024 - 2026) Analysis & Trends

MapLight Therapeutics has reported Research & Development for 2 years, with the latest figure at $64.6 million in Q4 2025.

  • Quarterly Research & Development rose 211.99% year-over-year to $64.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $129.2 million (changed N/A YoY) and the FY2025 annual result came in at $138.3 million, up 101.9% from the prior year.
  • Research & Development advanced to $64.6 million in Q4 2025 per MPLT's latest filing, from $27.1 million in the prior quarter.
  • Over five years, Research & Development peaked at $64.6 million in Q4 2025 and troughed at $16.8 million in Q3 2024.
Peer Set

Peer Comparison

All peers
# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Vertex Pharmaceuticals 138.51 Bn 130.66 Bn 2.84 Bn 993.80 Mn
2 Regeneron Pharmaceuticals 85.24 Bn 77.25 Bn 3.93 Bn 1.63 Bn
3 Argenx Se 63.46 Bn 58.28 Bn 1.37 Bn -486.00 Mn
4 Moderna 57.89 Bn 52.75 Bn 52.00 Mn 651.00 Mn
5 Revolution Medicines 44.02 Bn 44.02 Bn - 394.92 Mn
6 BeOne Medicines 39.95 Bn 34.85 Bn 1.53 Bn 612.28 Mn
7 Alnylam Pharmaceuticals 35.49 Bn 32.19 Bn 992.69 Mn 413.13 Mn
8 Royalty Pharma 28.43 Bn 27.59 Bn - 97.90 Mn
9 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 210.03 Mn
10 MapLight Therapeutics 636.95 Mn 636.95 Mn - 53.44 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 53.44 Mn
Dec 31, 2025 64.62 Mn
Sep 30, 2025 27.09 Mn
Jun 30, 2025 26.85 Mn
Dec 31, 2024 20.71 Mn
Sep 30, 2024 16.81 Mn